Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 12—December 2020
Research

Trends in Population Dynamics of Escherichia coli Sequence Type 131, Calgary, Alberta, Canada, 2006–20161

Gisele Peirano2, Tarah Lynch2, Yasufumi Matsumara2, Diego Nobrega, Thomas J. Finn, Rebekah DeVinney, and Johann D.D. PitoutComments to Author 
Author affiliations: University of Calgary Cummings School of Medicine, Calgary, Alberta, Canada (G. Peirano, T. Lynch, T.J. Finn, R. De Vinney, J.D.D. Pitout); Alberta Precision Laboratories, Calgary (G. Peirano, T. Lynch, J.D.D. Pitout); Kyoto University Graduate School of Medicine, Kyoto, Japan (Y. Matsumara); University of Calgary, Calgary (D. Nobrega); University of Pretoria, Pretoria, South Africa (J.D.D. Pitout)

Main Article

Table 1

Patient characteristics associated with Escherichia coli sequence type 131 clades, Calgary, Alberta, Canada, 2006–2016*

Characteristic Clade
A, n = 34 B, n = 32 C0, n = 5 C1-nonM27, n = 121 C1-M27, n = 13 C2, n = 139 All, n = 344
Year
2006 0a 14 (44)b,c 5 (100)b 24 (20)c 1 (8)a,c 9 (7)a 53 (15)
2012 18 (53) 9 (28) 0 56 (46) 4 (31) 63 (45) 150 (44)
2016
16 (47)
9 (28)
0
41 (34)
8 (34)
67 (48)
141 (41)
Sex
M 14 (41) 10 (31) 3 (60) 59 (49) 9 (69) 76 (55) 171 (50)
F
20 (59)
22 (69)
2 (40)
62 (57)
4 (31)
63 (45)
173 (50)
Mean age, y (range)
52.9 (1–87)
66 (8–103)
72 (57–79)
67.8 (1–95)
73.1 (45–92)
67.8 (9–94)

Clinical infection
Primary sepsis 13 (38)a 9 (28) 4 (80)a 15 (12)b 6 (46) 22 (16) 69 (20)
Urinary tract 15 (44) 14 (44) 1 (20) 66 (55) 6 (46) 84 (84) 186 (54)
Acute biliary 2 (6) 1 (3) 0 17 (1) 1 (8%) 10 (7) 31 (9)
Intraabdominal 3 (9) 4 (1) 0 7 (6) 0 9 (7) 23 (7)
Pneumonia
1 (3)
4 (13)
0
16 (13)
0
14 (10)
35 (10)
Origin of infection
Community-acquired 16 (47) 23 (72)a 4 (8) 31 (26)b 4 (31) 40 (29)b 118 (34)
Healthcare-associated 11 (32) 7 (22)a 0 70 (58)b 9 (69) 69 (50) 166 (48)
Hospital-acquired
7 (21)
2 (6)
1 (20)
20 (16)
0
30 (21)
60 (18)
Not susceptible
AMC 4 (12)a 5 (16)a 0a 34 (28)a 0a 85 (61)b 128 (37)
TZP 0 0 0 7 (6) 0 15 (11) 22 (6)
CRO 4 (12)a,b 1 (3)b 0a,b,d 40 (33)a,d 7 (54)c,d 94 (68)c 146 (42)
ERT/MEM 0 0 0 0 0 1 (1) 1 (0.3)
CIP 5 (1)a 0a 1 (20)a 121 (100)b 13 (100)b 139 (100)b 279 (81)
SXT 22 (65) 13 (41) 3 (60) 70 (58) 6 (46) 67 (48) 181 (53)
GEN 11 (32) 8 (25) 0 59 (49)a 0b 62 (45)a 140 (41)
TOB 10 (29)a,b 7 (22)a,b 0a,b 53 (44)a 0b 86 (62)c 156 (45)
AMK
0
0
0
0
0
1 (1)
1 (0.3)
Resistance score, median (range)†
1a,b (0–4)
1b (0–4)
1a,b (0–1)
3c (1–5)
2a,c (1–3)
4d (1–5)

Serotype
O16:H5 34 (100)a 0b 0b 0b 0b 0b 34 (10)
O25:H4 0a 31 (97)b 5 (100)b 121 (100)b 13 (100)b 139 (100)b 309 (90)
O2H4
0
1 (3)
0
0
0
0
1 (0.3)
fimH
41 33 (97)a 0b 0b 0b 0b 0b 33 (10)
89 1 (3) 0 0 0 0 0 1 (0.3)
22 0a 15 (47)b 0 0a 0a 0a 15 (4)
27 0a 12 (38)b 0 0a 0a 0a 12 (3)
324 0 1 (3) 0 0 0 0 1 (0.)
30
0a
4 (13)a
5 (100)b
121 (100)b
13 (100)b
139 (100)b
282 (82)
Plasmid type
Col (B551) 0 0 0 17 (14) 3 (23) 21 (15) 41 (12)
Col (MG828) 0 0 0 3 (2) 1 (8) 13 (9) 17 (8)
Col156 0a 8 (25)b 0 2 (2)a 1 (8%) 22 (16)b 33 (10)
Col8282 0 0 0 0 0 1 (1) 1 (0.3)
FIA 8 (32)a,b 1 (3)a 4 (80)b,c 110 (91)c 13 (100)c 125 (90)c 261 (76)
FIB 33 (97)a 28 (88) 4 (80) 102 (84)a 12 (92) 98 (71)b 277 (81)
FIC 1 (3) 7 (22) 0 6 (5) 0 35 (25) 49 (14)
FII 26 (76) 10 (31) 3 (60) 23 (19) 1 (3) 83 (60) 146 (42)
IncI1 3 (9) 2 (6) 1 (20) 16 (13) 1 (3) 8 (6) 31 (9)
IncN 1 (3) 1 (3) 1 (20) 6 (5) 1 (3) 7 (5) 17 (5)
IncX1 0 2 (6) 0 2 (2) 0 1 (1) 5 (1)
IncX4 1 (3) 1 (3) 0 6 (5) 2 (15) 9 (6) 19 (6)
IncY
0
0
0
0
0
7 (5)
7 (2)
IncF replicons
FII_1 6 (18)a 8 (25)a 0a 92 (76)b 12 (92)b 16 (12)a 134 (39)
FII_2 5 (15)a 1 (3)a,c 0a,c 105 (87)b 13 (100)b 2 (1)c 126 (37)
FIB_20 6 (1)a,c 1 (3)a,b 3 (60)c,d 97 (80)d 11 (85)d 2 (1)b 120 (35)
FII_2 1 (3)a 8 (25)b 1 (20) 19 (16)a,b 1 (8)a,b 63 (45)c 93 (27)
FIA_1
3 (9)a
0a
4 (80)b
2 (2)a
0a
69 (50)b
78 (23)
Grouped plasmids
Group 1 5 (15)a 1 (3)a,b 0a,b 80 (66)c 11 (85)c 0b 98 (28)
Group 2 0a 0a 1 (20) 0a 0a 56 (40)b 57 (17)

*Values are no. (%) unless indicated otherwise. Not susceptible include intermediate or resistant rates. Rates followed by different superscript letters indicate significant differences between clades at the 5% level (adjusted for multiple comparisons). Group 1 plasmids: combination of FIA_1, FII_2, and FIB_20. Group 2 plasmids: combination of FII_2 and FIA_1. AMC, amoxicillin/clavulanate; AMK, amikacin; CIP, ciprofloxacin; CRO, ceftriaxone; ERT, ertapenem; GEN, gentamicin; MEM, meropenem; SXT, trimethoprim/sulfamethoxazole; TOB, tobramycin; TZP, piperacillin/tazobactam.
†The resistance score was the number of antimicrobial drug classes to which resistance was detected.

Main Article

1Accepted as an oral presentation for the 30th European Congress of Clinical Microbiology and Infectious Diseases, Paris, France, April 18–21, 2020.

2These authors contributed equally to this article.

Page created: August 05, 2020
Page updated: November 19, 2020
Page reviewed: November 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external